On Tuesday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) opened lower -0.99% from the last session, before settling in for the closing price of $45.40. Price fluctuations for RARE have ranged from $37.02 to $60.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 63.06% over the past five years. Company’s average yearly earnings per share was noted 24.09% at the time writing. With a float of $83.35 million, this company’s outstanding shares have now reached $92.24 million.
Let’s look at the performance matrix of the company that is accounted for 1276 employees. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.
Ultragenyx Pharmaceutical Inc (RARE) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ultragenyx Pharmaceutical Inc is 9.74%, while institutional ownership is 92.12%. The most recent insider transaction that took place on Dec 10 ’24, was worth 413,650. In this transaction President & CEO of this company sold 8,273 shares at a rate of $50.00, taking the stock ownership to the 2,195,712 shares. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 8,273 for $50.00, making the entire transaction worth $413,650.
Ultragenyx Pharmaceutical Inc (RARE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Check out the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). In the past quarter, the stock posted a quick ratio of 2.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.46, a number that is poised to hit -1.34 in the next quarter and is forecasted to reach -5.12 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) saw its 5-day average volume 0.75 million, a negative change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 7.45%. Additionally, its Average True Range was 1.71.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 11.02%, which indicates a significant decrease from 11.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.72% in the past 14 days, which was lower than the 38.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $50.27, while its 200-day Moving Average is $47.98. Nevertheless, the first resistance level for the watch stands at $45.51 in the near term. At $46.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $46.66. If the price goes on to break the first support level at $44.35, it is likely to go to the next support level at $43.75. Assuming the price breaks the second support level, the third support level stands at $43.20.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
There are currently 92,344K shares outstanding in the company with a market cap of 4.15 billion. Presently, the company’s annual sales total 434,250 K according to its annual income of -606,640 K. Last quarter, the company’s sales amounted to 139,490 K and its income totaled -133,520 K.
